BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 524 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $163,053,449 | -21.7% | 2,395,379 | -6.2% | 0.03% | -17.5% |
| Q2 2023 | $208,357,963 | -8.8% | 2,552,468 | -17.1% | 0.04% | -11.1% |
| Q1 2023 | $228,452,896 | -14.3% | 3,079,295 | -4.3% | 0.04% | -15.1% |
| Q4 2022 | $266,573,823 | +10.4% | 3,216,383 | +278.2% | 0.05% | +3.9% |
| Q3 2022 | $241,545,000 | +9.2% | 850,510 | +33.2% | 0.05% | +13.3% |
| Q2 2022 | $221,285,000 | +11.8% | 638,373 | +39.7% | 0.04% | +32.4% |
| Q1 2022 | $197,870,000 | +7.6% | 456,934 | +28.6% | 0.03% | +17.2% |
| Q4 2021 | $183,846,000 | +33.5% | 355,367 | +25.1% | 0.03% | +26.1% |
| Q3 2021 | $137,677,000 | +0.8% | 284,122 | -6.3% | 0.02% | 0.0% |
| Q2 2021 | $136,553,000 | +17.7% | 303,275 | -0.2% | 0.02% | +15.0% |
| Q1 2021 | $116,029,000 | +5.8% | 303,794 | -12.0% | 0.02% | 0.0% |
| Q4 2020 | $109,679,000 | -39.1% | 345,392 | -52.5% | 0.02% | -45.9% |
| Q3 2020 | $180,242,000 | -38.6% | 727,578 | -34.5% | 0.04% | -43.1% |
| Q2 2020 | $293,387,000 | -1.2% | 1,111,019 | -29.0% | 0.06% | -17.7% |
| Q1 2020 | $296,845,000 | -16.9% | 1,565,469 | -3.8% | 0.08% | +5.3% |
| Q4 2019 | $357,389,000 | +9.6% | 1,628,121 | -2.3% | 0.08% | +1.4% |
| Q3 2019 | $326,173,000 | +1.4% | 1,666,953 | +8.1% | 0.07% | +4.2% |
| Q2 2019 | $321,546,000 | +4.9% | 1,542,258 | -0.1% | 0.07% | +2.9% |
| Q1 2019 | $306,433,000 | +64.6% | 1,543,356 | +20.0% | 0.07% | +46.8% |
| Q4 2018 | $186,187,000 | -3.8% | 1,286,532 | +35.6% | 0.05% | +14.6% |
| Q3 2018 | $193,583,000 | +655.5% | 948,424 | +447.6% | 0.04% | +583.3% |
| Q2 2018 | $25,623,000 | -1.2% | 173,186 | +0.9% | 0.01% | 0.0% |
| Q1 2018 | $25,927,000 | +16.0% | 171,660 | -0.5% | 0.01% | +20.0% |
| Q4 2017 | $22,343,000 | +17.7% | 172,457 | +9.8% | 0.01% | +25.0% |
| Q3 2017 | $18,979,000 | +35.8% | 156,995 | +32.0% | 0.00% | +33.3% |
| Q2 2017 | $13,980,000 | -6.4% | 118,977 | -19.0% | 0.00% | -25.0% |
| Q1 2017 | $14,940,000 | -67.2% | 146,964 | -66.8% | 0.00% | -63.6% |
| Q4 2016 | $45,484,000 | -1.9% | 442,320 | +4.5% | 0.01% | -8.3% |
| Q3 2016 | $46,343,000 | -15.4% | 423,221 | -12.9% | 0.01% | -14.3% |
| Q2 2016 | $54,764,000 | +63.2% | 485,628 | +36.8% | 0.01% | +55.6% |
| Q1 2016 | $33,563,000 | +11.1% | 355,089 | +5.8% | 0.01% | +12.5% |
| Q4 2015 | $30,210,000 | +10.8% | 335,665 | +13.8% | 0.01% | 0.0% |
| Q3 2015 | $27,273,000 | +0.5% | 294,975 | +7.0% | 0.01% | +14.3% |
| Q2 2015 | $27,149,000 | +218.3% | 275,700 | +224.2% | 0.01% | +250.0% |
| Q1 2015 | $8,529,000 | +36.8% | 85,040 | +26.0% | 0.00% | 0.0% |
| Q4 2014 | $6,234,000 | – | 67,470 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |